Global Gothenburg: A cross-section of AstraZeneca – on one site
With more than 2,400 employees from 50 countries, the vibrant Gothenburg site helps to support the entire life-cycle of AstraZeneca medicines, from drug discovery and clinical trials, to global commercialisation and product maintenance. Looking to the future, AZ Gothenburg has initiated the creation of a new, global cluster for health and life science, as part of the GoCo Health Innovation City project.
From idea to new medicine
Our teams in Gothenburg have broad scientific expertise and capabilities and work across the entire life-cycle of our medicines.
Our team of world-renowned scientists collaborate to support the identification and validation of targets regulating biological processes which are the fundamental drivers of human disease. Using a variety of tools, including in vivo and in vitro assays and bio-informatic approaches, our Gothenburg-based scientists rigorously test biological hypotheses across two of AstraZeneca’s three core science units: Cardiovascular and Metabolic Diseases and Respiratory, Inflammation and Autoimmunity.
Our medicinal chemistry capabilities enable us to integrate structural, pharmacological, pharmacokinetic and toxicological information to support the innovative design of novel chemical compounds. Pushing the boundaries of medicinal chemistry enables the delivery of new candidate drugs into our pipeline, and is the foundation of small molecule drug discovery across the company.
Our translational expertise enables us to accelerate drug development in human disease by selecting the right patients in early clinical trials. We accomplish this by embedding human target validation earlier in research, utilising innovative clinical trial design approaches and integrating multiple, relevant scientific insights across our focus areas.
As a leader in personalised healthcare, we are committed to matching new medicines to the patient most in need. We combine industry-leading expertise in companion diagnostics with laboratory science in molecular diagnostics, tissue diagnostics, imaging and protein biomarkers, and we work collaboratively with our external partners to harness breakthrough technologies across the life-cycle of our medicines.
Our Pharmaceutical Development team designs and delivers the active drug products needed to support new medicines across our portfolio. This includes formulations, devices and packaging as well as demand planning to support global clinical trials in all phases. They also develop the latest in digital health solutions to help patients maximise the benefits of their medicines for better health outcomes.
Our Early Clinical Development team designs and delivers early phase development strategies and exploratory studies that build the credentials of novel targets. Clinical Operations delivers global clinical trials for late stage projects across our pipeline, using both internal and external programme and study management expertise. Our teams are especially experienced in cardiovascular and respiratory diseases and in managing large outcome studies in partnership with Academic Research Organisations.
"At AstraZeneca, science and patients are always in focus. As a scientist I love being able to work with people from different disciplines to turn scientific ideas into new medicines for patients in need."
Lab4Life: Building state-of-the-art shared labs and offices for the future
Lab4Life is a driving force in our work to make Gothenburg one of the best R&D sites in the world. The philosophy of Lab4Life is to create flexible lab and office working environments that encourage collaboration between scientists from different therapy areas and disciplines. Lab4Life includes more than 10 new Centres of Excellence, including centres for Chemistry, Mass Spectrometry, Cells, Sample Management, and more. The Lab4Life initiative has already inspired other labs across both our company and the industry. Watch this new film to follow one of our scientists, Anita, as she spends a day in these new, shared state-of-the-art spaces.
Open for collaboration
100 million USD
Investment in Karolinska Institutet partnership
Academic collaborations signed 2014/2015 by Gothenburg site
of cardiovascular and metabolic disease pipeline involves collaboration
BioVentureHub: a new way to collaborate
The AstraZeneca BioVentureHub is an exciting concept. We offer some of our office and laboratory space in Gothenburg to biotech companies and academic groups. This is a cost-effective opportunity for biotech start-ups to benefit from our scientific expertise and facilities, plus opportunities for future collaborations. We benefit through increasing external interaction and vibrancy while also nurturing the Scandinavian life science ecosystem.
Gothenburg key facts
Employees on site
Scientists from 50 countries
Scientists with PhDs
Professors among our scientists
Our community commitment
AstraZeneca works actively to foster interest in life sciences among children and young adults in Sweden. We also support programmes under the umbrella of our global Young Health Program, which focuses on mental and physical health among children and adolescents.
AstraZeneca has been Principal Partner of Scandinavia’s largest science park for over 10 years. During this time, we have been involved in several joint projects, incluidng Medicinjakten, Hänget and Molekul.Learn more
The International Science Festival
‘Vetenskapsfestivalen’ is one of Europe’s leading popular science events for school children and attracts more than 70,000 visitors annually.Learn more
Mentorship and volunteering
Together with Mentor Sweden, our colleagues act as mathematics mentors for students at the nearby school Katrinebergsskolan. Many of us are also engaged in projects that directly and indirectly contribute to the well-being and mental health of children and adolescents, through a collaboration with ‘Volontärbyrån’.
Lean more about:
We partner with others around the world, combining the great science in our labs with complementary technologies, know-how and molecules to accelerate the delivery of new life-changing medicines.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.